Have any questions? 706-721-6582 or cts@augusta.edu
- GS-US-380-4580: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Clinical Trial
GS-US-380-4580: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
This study will look at African American adults with HIV who switch from their current anti-HIV treatment to a new combination pill for HIV treatment.
Eligibility Criteria
- Inclusion: 1. Adults at least 18 years old who are HIV-positive, describe themselves as Black, African American, or mixed race including Black, and on stable HIV therapy for at least 6 months. 2. HIV count less than 50 for at least 6 months. 3. Lab tests within study-specified ranges. Exclusion: 1. No current or past medical conditions not allowed by the study. 2. No requirement to take medications not allowed by the study. 3. Women cannot be pregnant or breastfeeding.
RESEARCH. INNOVATION. DISCOVERY.